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Introduction: Bortezomib is a small-molecule proteasome inhibitor
with single-agent activity in patients with non-small cell lung
carcinoma (NSCLC) and synergy with gemcitabine in preclinical
studies. The combination of gemcitabine and carboplatin is an
accepted first-line treatment for advanced NSCLC. We conducted a
phase I study of gemcitabine and carboplatin in combination with
bortezomib.
Methods: Bortezomib was administered on days 1, 4, 8, and 11,
after gemcitabine on days 1 and 8, and carboplatin on day 1 of a
21-day cycle. Three escalating dose levels were evaluated: bort-
ezomib 1.0 mg/m2/gemcitabine 800 mg/m2, bortezomib 1.0 mg/m2/
gemcitabine 1000 mg/m2, and bortezomib 1.3 mg/m2/gemcitabine
1000 mg/m2, in combination with carboplatin AUC 5.0.
Results: Twenty-six patients with advanced NSCLC were treated;
21 were chemotherapy-naive. The median age was 59 years (range,
34–74), and 23 patients were stage IV. The Karnofsky performance
score was 80% in 10 and 80% in 16 patients. Dose-limiting
toxicities were grade 3 thrombocytopenia with bleeding and febrile
neutropenia accompanied by grade 4 thrombocytopenia and grade 3
hyponatremia. The maximum-tolerated dose was defined as bort-
ezomib 1.0 mg/m2, gemcitabine 1000 mg/m2, and carboplatin AUC
5.0. The most common grade 3/4 toxicities were thrombocytopenia
(rarely associated with bleeding), and neutropenia. Nine of 26
patients (35%) achieved partial response, and eight patients had
stable disease.
Conclusions: The combination of bortezomib 1.0 mg/m2, gemcit-
abine 1000 mg/m2, and carboplatin AUC 5.0 demonstrated manage-
able toxicities and encouraging activity in NSCLC. This regimen
was used in a phase II study.
Key Words: Bortezomib, Carboplatin, Gemcitabine, Non-small cell
lung cancer, Proteasome inhibitor.
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Platinum-based therapy remains the standard first-linetreatment of patients with advanced non-small cell lung
carcinoma (NSCLC) in North America. Among the available
platinum agents, carboplatin is often preferred because of its
more favorable toxicity profile compared with cisplatin.1,2
Although many agents (paclitaxel, docetaxel, and gemcitab-
ine) have been combined with platinum to improve outcomes
in advanced NSCLC, response rates with these doublets have
ranged from 19 to 28%,with median survival of 7.9 to 11.3
months.3–5 In randomized trials, the combination of gemcit-
abine with carboplatin has produced superior response rates,
similar or improved median survival, and toxicity comparable
to that of cisplatin with gemcitabine or vinblastine.6–8 Be-
cause of its favorable toxicity profile and efficacy, the com-
bination of gemcitabine and carboplatin has been recom-
mended as a foundation on which to develop innovative
combinations using novel agents.9–11
Bortezomib (VELCADE, Millennium Pharmaceuti-
cals, Inc., Cambridge, MA, and Johnson & Johnson Pharma-
ceutical Research & Development, L.L.C., Raritan, NJ) is a
novel antineoplastic agent and is a selective reversible protea-
some inhibitor. Bortezomib binds to and inhibits the proteasome
chymotryptic subunit while enhancing tryptic activity, and the
ratio of chymotryptic and tryptic activity can therefore be used
as an ex vivo gauge of bortezomib activity.12 The multicatalytic
proteasome complex is critical to the regulated degradation of
intracellular proteins involved in proliferation and apoptosis.
Proteasome inhibition causes disruption in protein homeostasis
that adversely affects intra- and intercellular signaling cas-
cades.13–17 Loss of the cyclin-dependent kinase inhibitor p27KIP1
and overexpression of the antiapoptotic regulator Bcl2 are asso-
ciated with poor prognosis in NSCLC.18–21 Bortezomib may
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minimize the adverse effect of these prognostic factors
through the mechanism of proteasome inhibition increas-
ing p27KIP1 levels and down-regulating levels of Bcl2
expression.21 Bortezomib is already known to induce growth
inhibition and apoptosis of lung cancer cells,15–17 and in
patients with NSCLC, bortezomib has demonstrated antitu-
mor activity in phase I/II trials.22,23
In addition to its direct antitumor effect, proteasome
inhibition sensitizes neoplastic cells to the apoptotic effects of
other antineoplastic agents. Treatment with gemcitabine and
carboplatin elicits the activation of nuclear factor (NF)-B
and transcription of its downstream genes, which can lead to
the development of chemoresistance.24–27 The ability of bort-
ezomib to prevent NF-B activation is considered critical to
the mediation of its antineoplastic and chemosensitizing
properties.28,29
The addition of bortezomib to gemcitabine in vitro
demonstrates synergistic antitumor activity,16,30 and in phase
I trials, there was no additive toxicity associated with the
combination.31 Myelosuppression has been the major toxicity
of gemcitabine, especially when combined with carboplatin,
but it can be tempered by schedule adjustment. Because there
is a higher rate of grade 3 or 4 thrombocytopenia with
gemcitabine on a 28-day schedule32–34 relative to a 21-day
schedule11,35 and the response rates with the shorter schedule
are in the range of most active regimens, the 21-day cycle is
now more commonly used.11
The primary objective of this phase I study was to
evaluate the safety and feasibility of combining bortezomib
with gemcitabine and carboplatin in patients with advanced
or recurrent NSCLC. The secondary objectives were to define
the maximum tolerated dose level (MTD) of this combination
and to obtain preliminary efficacy data.
PATIENTS AND METHODS
Study approval was obtained from the institutional review
boards of all participating centers before patient accrual in
accordance with Federal and institutional guidelines. All patients
provided written informed consent before enrollment.
Patient Selection
Patients aged 18 years or older with histologically or
cytologically confirmed evaluable stage IIIB (malignant pleu-
ral effusion) or stage IV NSCLC or recurrent disease after
previous surgery or radiation were eligible for enrolment.
Neurologically stable patients with treated asymptomatic
brain metastases were eligible, provided they had not re-
quired corticosteroids for at least 4 weeks before enrollment.
One prior therapy, which must have been completed 4
or more weeks before the start of treatment, was permitted,
but in the expanded cohort at the MTD, prior chemotherapy
was not permitted. Patients who received previous platinum-
based chemotherapy must have progressed 3 or more months
after chemotherapy completion.
Other inclusion criteria included Karnofsky perfor-
mance status 60%, serum creatinine  upper limit of
normal or creatinine clearance 50 mL/min, absolute neu-
trophil count 1500/L, platelet count 100,000/L, and
adequate hepatic function (serum bilirubin 1.5 mg/dL and
aspartate transaminase2.5 times the upper limit of normal).
Patients were excluded if they had received previous
treatment with gemcitabine or bortezomib, were receiving
treatment for human immunodeficiency virus infection, had
grade1 peripheral neuropathy at baseline, or were pregnant
or nursing.
Study Design
Bortezomib was administered by 3- to 5-second intra-
venous bolus that was initially performed 1 hour before a
30-minute intravenous infusion of gemcitabine. This treat-
ment was followed by a 15- to 30-minute carboplatin infusion
for all patients at the first two dose levels and for three of
seven patients at the third dose level. With the availability of
preclinical data demonstrating sequence-specific effects,16 the
protocol was amended such that bortezomib was adminis-
tered 1 hour after infusions of gemcitabine and carboplatin
for four of seven patients at the third dose level and for the
additional 10 patients treated at the MTD.
In the dose-escalation portion of the study, doses of
bortezomib and gemcitabine were increased, whereas carbo-
platin AUC remained constant over a 21-day dosing scheme
for the first three dose levels (Table 1). Treatment continued
for six cycles, unless unacceptable toxicity, disease progres-
sion, withdrawal, treatment delay of longer than 4 weeks, or
illness preventing continuation of treatment occurred. Pa-
tients with a clinical or radiographic response continued to
receive bortezomib monotherapy beyond six cycles twice
weekly at the same dose. Routine use of granulocyte colony-
stimulating factor was not allowed.
Dose-limiting toxicities (DLTs) were defined using the
National Cancer Institute (NCI) Common Toxicity Criteria
(CTC), version 2.036: grade 4 thrombocytopenia 10,000/L;
grade 3 thrombocytopenia 50,000/L with bleeding, trans-
fusion requirement, or persisting more than 7 days; febrile
neutropenia; grade 4 neutropenia lasting 7 days; or any
grade 3 nonhematologic toxicity occurring in cycle 1 at-
tributed to study drugs, with the exception of alopecia or
inadequately treated nausea, vomiting, or diarrhea.
The MTD was the highest dose administered at which
fewer than 33% of patients experienced a DLT. Three pa-
tients were entered into each dose level. Occurrence of one
DLT required the entry of at least three more patients at that
dose level. After the MTD was established, 10 additional
patients with chemotherapy-naive disease received the MTD.
TABLE 1. Treatment Schedule, 21-Day Cycle
Dose
Level
Bortezomib,
mg/m2
Gemcitabine,
mg/m2
Carboplatin
AUC
Days 1, 4, 8, 11 Days 1, 8 Day 1
1 1.0 800 5.0
2 1.0 1,000 5.0
3 1.3 1,000 5.0
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Dose Modification
Doses of study drugs were modified according to interim
toxicities. All dose reductions were permanent. Routine use of
granulocyte colony stimulating factors was not recommended.
Evaluation
All patients were evaluated for response after every
two cycles (at 6 weeks), and responses were assessed using
the standard Response Evaluation Criteria in Solid Tumors
(RECIST).37 An event for progression-free survival was
defined as progression or death. Adverse events were graded
using NCI CTC version 2.0.36
Molecular Correlative Studies and Proteasome
Inhibition Analysis
Basal tumor levels of p27KIP1 and BclII proteins were
assessed by immunochemistry in tissue samples obtained
from consenting patients. Abnormal loss of p27KIP1 (lack of
staining in more than 40% of tumor cells) or overexpression
of BclII (positive cytoplasmic staining of more than 10% of
tumor cells) was correlated with patient outcomes; data were
to be hypothesis-generating as the number of patients pre-
cluded any correlative statistical significance.
In addition, whole blood samples for proteasome inhi-
bition assay were obtained from consenting patients before
bortezomib dosing on days 1 and 8 of cycle 1 and day 1 of
cycle 2 (day 22). Pharmacodynamic analysis of bortezomib-
induced proteasome inhibition was conducted via measure-
ment of chymotryptic and tryptic activity within the 20S
proteasome core.12 The purpose of this analysis was to
determine the residual activity of bortezomib before the day
8 and day 22 treatments.
RESULTS
Patient Characteristics
Twenty-six patients were enrolled: 16 in the dose-
escalation groups and 10 in the expanded group at the MTD.
By protocol, all patients in the expanded group were chemo-
therapy-naive, as were 11 patients in the dose-escalation
groups. Of the five patients who had previously received
chemotherapy, one had received single-agent treatment and
four had received a multiple-agent regimen. Ten patients
had a Karnofsky performance score80%, and most patients
had undergone prior surgical intervention (Table 2).
Treatment Administered, Dose Modifications,
and Interruptions
The median number of cycles administered was four. In
the first two dose levels, one patient on dose level 2 required a
dose reduction because of a grade 4 thrombocytopenia requiring
a platelet transfusion (cycle 1, DLT); a second patient at this
dose level also required a dose reduction for a DLT of grade 3
thrombocytopenia with hemoptysis. No dose interruptions were
reported at dose level 2. At dose level 3 therapy was discontin-
ued for one patient because of grade 4 thrombocytopenia, febrile
neutropenia, and grade 3 hyponatremia (cycle 1, DLT), and in
another patient because of a DLT of grade 4 neutropenia and
grade 3 thrombocytopenia with bleeding into tumor in the renal
pelvis. In addition, the dose was reduced in one patient, and
treatment was interrupted in another patient twice because of
neutropenia. Although these events occurred in cycle 1, they did
not meet the criteria of DLT. Counts recovered in both patients,
and treatment resumed.
DLT and MTD
No DLT was observed at the first dose level (Table 3).
Among the first three patients at the second dose level, one
patient experienced a DLT, grade 3 thrombocytopenia (plate-
let count 26,000/L) with minor hemoptysis, necessitating
enrollment of three additional patients. No further DLT was
observed, and accrual into the third dose level proceeded.
Among the first three patients at the third dose level, one
patient who did not receive the full dose per protocol was
inevaluable and was replaced. One DLT, grade 4 neutropenia
and grade 3 thrombocytopenia (27, 000/L) with bleeding
into the renal pelvis in a patient with large bilateral renal
metastases, was observed among the first three evaluable
patients, and three additional patients were enrolled. One of
these patients experienced DLT at dose level 3 (febrile
neutropenia and grade 4 thrombocytopenia [9,000/L] with-
out bleeding and grade 3 hyponatremia). Therefore, the prior
dose level, bortezomib 1.0 mg/m2, gemcitabine 1,000 mg/m2,
and carboplatin AUC 5.0, was declared the MTD. Ten che-
motherapy-naive patients were entered into an expanded
TABLE 2. Baseline Characteristics
Characteristic
No. Patients
(n  26)
Median age, yr (range) 59 (34–74)
Sex
Male 14
Female 12
Race
White 24
Asian 1
Unknown 1
Tumor type
NSCLC, not otherwise specified 14
Adenocarcinoma, not otherwise specified 10
Bronchioloalveolar carcinoma 1
Squamous cell carcinoma 1
Prior therapy
Surgery 25
Radiation 3
Prior drug therapy 6
KPS
100% 5
90% 11
80% 5
70% 4
60% 1
Stage
III 3
IV 23
NSCLC, non-small cell lung carcinoma; KPS, Karnofsky performance score.
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cohort at dose level 2 for further assessment of toxicity and
efficacy. Only one of these patients developed a DLT (grade
4 thrombocytopenia).
Toxicities
Hematologic toxicities were the most frequent grade
3/4 events (Table 4). Grade 3/4 thrombocytopenia oc-
curred in 12 of 26 patients and was dose related, occurring
in 1 of 3 patients (33%) at dose level 1, 6 of 16 (38%) at
dose level 2, and 5 of 7 (71%) at dose level 3. Grade 4
thrombocytopenia occurred in one patient at dose level 2
(cycle 1, DLT) and in one patient at dose level 3 (cycle 1,
DLT). Other than bleeding into the renal pelvis in a patient
with large bilateral renal metastases reported above, bleed-
ing occurred in only 2 other patients, both with grade 3
thrombocytopenia. One patient at dose level 2 experienced
grade 3 hemoptysis, and one patient at dose level 3 had
grade 3 hemorrhage.
Neutropenia and leukopenia was also dose related. No
grade 4 neutropenia or leukopenia occurred at dose levels 1 or 2,
but at dose level 3, two patients experienced grade 4 leukopenia,
and three patients experienced grade 4 neutropenia.
There were no grade 4 nonhematologic toxicities attrib-
uted to treatment. Grade 3 nonhematologic toxicities were
primarily gastrointestinal complaints (abdominal cramping
and diarrhea) or electrolyte imbalances (hypophosphatemia,
hypocalcemia, hypokalemia). Fatigue, dyspnea, hyperglyce-
mia, constipation, hypoalbuminemia, and nausea were the
most frequent nonhematologic toxicities of any grade. Except
for nausea, none of these events seemed to be dose related.
There were no treatment-related deaths.
Antitumor Activity
Twenty of 26 patients were evaluable for response
(Table 5). Of the remaining six patients, two patients had only
one cycle of treatment, three patients went off study on cycle
1 due to an adverse event, and one patient was not assessable
and did not receive a full dose. Partial response was achieved
in 9 of 26 patients (35%), including one at dose level 1, 6 at
dose level 2, and 2 at dose level 3. Stable disease was
observed in eight patients, including one patient at dose level
1, five patients at dose level 2, and two patients at dose level
3. Three patients, all of whom were on dose level 2, pro-
gressed on therapy. Two patients received bortezomib mono-
therapy beyond six cycles. Among all 26 patients, the median
progression-free survival was 4 months, and the median
overall survival was 9 months.
Correlative Studies
Immunohistochemical analyses of Bcl2 and p27KIP1
were performed on 16 archival tumor specimens from 11
TABLE 3. Dose-Limiting Toxicities During Cycle 1 by Dose
Level
Dose
Level
No.
Patients
Dose-limiting
Toxicity, No.
of Patients Dose-limiting Toxicities
1 3 0 —
2 16 2a Grade 3 thrombocytopenia (platelet
count 26,000/L), with minor
hemoptysis
Grade 4 thrombocytopeniaa
3 7b 2 Grade 4 neutropenia and grade 3
thrombocytopenia (platelet count
27,000/L) with bleeding into
tumor in renal pelvis
Febrile neutropenia and grade 4
thrombocytopenia (platelet count
9,000/L) without bleeding and
grade 3 hyponatremia
a One of the 2 dose-limiting toxicities occurred in a patient enrolled in the expanded
group at the maximum tolerated dose.
b One patient not evaluable.
TABLE 4. Treatment-Related Grade 3/4 Toxicities
Toxicity
Dose Level 1,
No. of Patients
(n  3)
Dose Level 2,
No. of Patients
(n  16)
Dose Level 3,
No. of Patients
(n  7)
Total No.
of Patients
(n  26)
Thrombocytopenia 1 6 5 12
Neutropenia 0 4 4 8
Leukopenia 0 3 4 7
Lymphopenia 0 2 2 4
Anemia 0 1 0 1
Fever 0 0 1 1
Infection 0 0 1 1
Hypokalemia 0 1 0 1
Hypocalcemia 0 1 0 1
Hypophosphatemia 0 1 0 1
Hyponatremia 0 0 1 1
Diarrhea 0 1 0 1
Abdominal cramping 0 1 0 1
Hemoptysis 0 1 0 1
Hemorrhage 0 0 1 1
Dyspnea 0 0 1 1
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patients. None of the tumors showed aberrant staining pat-
terns of Bcl-2. In contrast, all but two patients exhibited
abnormally low p27 staining. No correlations between
marker expression and patient outcome were observed.
Proteasome Inhibition Analysis
Whole blood samples were available at all three specified
time points (days 1 and 8, cycle 1, and day 1, cycle 2 [day 22])
from 13 patients. In these patients, the chymotryptic-to-tryptic
(ChT:T) ratio remained significantly decreased at both day 8 and
at day 22 compared with pretreatment values (two-factor re-
peated ANOVA, p  0.0001; Figure 1), reflecting residual
bortezomib-induced proteasome inhibition. The median ChT:T
ratio before treatment on day 1, cycle 1, was 1.04, decreasing to
0.77 on day 8, cycle 1, and returning to 0.92 by day 1, cycle 2
(day 22). Although all patients showed a decrease from baseline,
9 of 13 patients exhibited an increase between day 8 and day 22,
which was also significant (Duncan’s multiple range test with an
alpha of 0.05).
DISCUSSION
Platinum-based chemotherapy provides unequivocal
benefit in the treatment of advanced NSCLC, yet no clear
superiority has been demonstrated for any single doublet.
Gemcitabine and carboplatin in a 21-day schedule has
emerged as a commonly used regimen for advanced NSCLC,
and median survival is less than a year. Thus, this regimen
has been suggested as a platform on which to evaluate new
triplets that offer the potential for greater efficacy. Such an
approach has been validated in a phase III Eastern Coopera-
tive Oncology Group study, the results of which were pub-
lished following completion of this phase I trial, which
demonstrated superior survival with addition of bevacizumab
to the doublet of paclitaxel and carboplatin in patients with
advanced nonsquamous NSCLC.38
In this phase I trial, bortezomib was added to gemcit-
abine-carboplatin to evaluate safety and tolerability and to
determine an optimal dose for phase II testing. The recom-
mended phase II dose was determined to be bortezomib 1.0
mg/m2 on days 1, 4, 8, and 11, gemcitabine 1000 mg/m2 on
days 1 and 8, and carboplatin AUC 5.0 on day 1 of a 21-day
cycle. Doses of these agents are within the reported thera-
peutic range as monotherapy or in combination with other
treatments.7,8,11,39 In addition, this combination demonstrated
encouraging activity in patients with advanced NSCLC, with
a 35% response rate. The combination of bortezomib, gem-
citabine, and carboplatin was associated with manageable
toxicities, of which the most common was thrombocytopenia.
Thrombocytopenia with bortezomib monotherapy is transient
and cyclical, reaching a nadir during the dosing phase and
recovering toward baseline during the day 12 to 21 rest
phase.39–41 The rapid platelet count recovery in the clinical
setting and the lack of lethality to hematopoietic progenitor
cells in murine models suggest that bortezomib temporarily
stuns megakaryocytes, preventing cytoplasmic platelet bud-
ding, but these effects are short-lived.42 Thrombocytopenia is
also a common toxicity of gemcitabine, but it is less frequent
and less severe with once-weekly dosing for 2 weeks of a
3-week cycle compared with once-weekly dosing for 3 weeks
of a 4-week schedule.11,35 Thrombocytopenia is the predom-
inant DLT of carboplatin, and it is cumulative in nature.43
The observation that these three agents can be combined at
therapeutic doses, despite a potentially overlapping toxicity
profile, with very few patients requiring dose reduction at the
MTD, suggests that the toxicities are not additive. Neurotox-
icity was not a DLT with the triplet. Grade 1 sensory
FIGURE 1. Ex vivo measurements of chymotryptic (ChT)
and tryptic (T) activity within the 20S proteasome core from
all whole blood circulating cells. The ratio of ChT:T activity
indicates bortezomib-induced proteasome inhibition. Solid
lines indicate patients who responded to treatment and
dashed lines indicate patients who progressed on therapy.
Blood samples were drawn before therapy (baseline, day 1,
cycle 1), before day 8, cycle 1 treatment, and before dosing
on day 1, cycle 2 (day 22).
TABLE 5. Best Response by Dose Level and Overall
Best Response
Dose Level 1,
No. of Patients
(n  3)
Dose Level 2,
No. of Patients
(n  16)
Dose Level 3,
No. of Patients
(n  7)
Total No.
of Patients
(n  26)
Partial response 1 6 2 9
Stable disease 1 5 2 8
Progressive disease 0 3 0 3
Not evaluable 0 2 3 5
Not assessable 1 0 0 1
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neuropathy was reported in only three patients receiving
bortezomib 1.3 mg/m2 (dose level 3).
The pharmacokinetics of gemcitabine and carboplatin
in the presence of bortezomib were not evaluated in the
present study. Nevertheless, given the known routes of elim-
ination of the three agents, it is very unlikely that bortezomib
alters the pharmacokinetics of either gemcitabine or carbo-
platin. Bortezomib is primarily eliminated through hepatic
metabolism by CYP3A4 and CYP2C19, whereas carboplatin
is almost exclusively cleared through renal filtration and
gemcitabine is ubiquitously converted to both active and
inactive metabolites in tissues expressing deoxycytidine ki-
nase and cytidine deaminase, respectively. Indeed, in a recent
report of a phase I trial combining bortezomib with gemcit-
abine and cisplatin in patients with advanced solid tumors,
including NSCLC, bortezomib did not affect the pharmaco-
kinetics of either agent.44
Identification of the optimal sequence of administration
of antineoplastic agents is critical to maximize the antitumor
activity of each one. Preclinical studies supported sequence-
specific efficacy with the doublet bortezomib and gemcitab-
ine and with the triplet bortezomib, gemcitabine, and carbo-
platin.16,45 The emergence of preclinical findings showing an
antitumor advantage to bortezomib administration after or
with the other agents convinced us to amend our protocol to
align with that evidence. It is hypothesized that sequence-
specific efficacy may be related to distinct cell cycle arrest
checkpoints with bortezomib (G2/M),15 gemcitabine (G0/G1),46
and carboplatin (S/G2),47 such that pretreatment with bort-
ezomib would prevent cycling through phases before G2/M
and may result in less apoptosis from gemcitabine and car-
boplatin.16 Although preclinical data support schedule depen-
dency, the small sample size of this study makes it difficult to
determine any differences in toxicity or clinical efficacy with
different bortezomib schedules. It may be noted that in the
recent phase I trial of bortezomib plus gemcitabine and
cisplatin, in which bortezomib was administered before gem-
citabine and cisplatin, a similar level of activity to that seen
in the present study was observed.44 An ongoing California
Cancer Consortium study evaluating two different schedules
of bortezomib in combination with docetaxel as second-line
therapy in patients with advanced NSCLC may shed light on
the concept of schedule dependency. Furthermore, in the
study of bortezomib plus gemcitabine and cisplatin, weekly
and biweekly schedules of bortezomib administration re-
sulted in similar activity.44 A phase 1 study nearing comple-
tion at University of California Davis is evaluating a once-
weekly bortezomib dosing schedule in combination with
gemcitabine and carboplatin.
Molecular correlative studies did not reveal any relation-
ship between Bcl2 or p27KIP1 expression and patient outcomes
because of the small patient population. Pharmacodynamic anal-
ysis of bortezomib-induced proteasome inhibition revealed sig-
nificant residual inhibition at day 8, cycle 1, and day 1, cycle 2
(day 22), relative to pretreatment levels, with the median degree
of inhibition recovering significantly toward baseline between
these time points during the rest period in bortezomib dosing.
The pattern of proteasome inhibition during bortezomib treat-
ment reflects previous reports.48,49
Treatment with bortezomib in combination with gemcit-
abine and carboplatin yielded encouraging responses with a
manageable toxicity profile in NSCLC. The present study
formed the basis for the Southwest Oncology Group phase II
trial (S0339, NCT00075751) of this combination for the first-
line treatment of patients with advanced NSCLC utilizing the
MTD established here.
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